- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries | ||
| Mi | JPM26: Bayer evades patent cliff in a way it may not be able to repeat | ||
| Mi | JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition | ||
| Mi | Drugmakers welcome FDA's GLP-1RA suicide warning removal request | ||
| Mi | JPM26: Tryngolza set to become first wholly owned Ionis blockbuster | ||
| Mi | JPM26: 2025 a "breakout year" for rare disease biotechs | ||
| Mi | JPM26: BioNTech gears up for multiproduct oncology status by 2030 | ||
| Mi | JPM26: Amgen touts MariTide's weight loss, T2D potential off Phase II data | ||
| Mi | BD invests $110m to expand US prefillable syringe production | ||
| Mi | Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease | ||
| Di | JPM26: GSK banks on recent AI deals to offset patent expiries | ||
| Di | JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery | ||
| Di | JPM26: J&J leans on immunology launches to fuel annual growth | ||
| Di | JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease | ||
| Di | JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff | ||
| Di | JPM26: Sarepta CEO touts "avalanche of Elevidys data" amid 2025 safety woes | ||
| Di | JPM26: HIV pipeline dosing optionality gives Gilead advantage | ||
| Di | AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D | ||
| Di | JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff | ||
| Di | SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody | ||
| Di | JPM 26: Day 1 - drug prices and policy changes drive the agenda | ||
| Di | Atara receives FDA complete response letter for Ebvallo BLA application | ||
| Mo | JPM26: Anthropic advances healthcare presence with new AI toolkit | ||
| Mo | JPM26: Eli Lilly and NVIDIA deepen ties with $1bn AI partnership | ||
| Mo | JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .